PD-L1 expression

P2, N=63, Completed, IO Biotech | Active, not recruiting --> Completed | Trial completion date: Nov 2024 --> Feb 2026 | Trial primary completion date: Jan 2024 --> Nov 2025

To solve this problem, we encapsulate ECN with a hybrid film of metformin (Met) and a Lipo membrane by electrostatic adsorption to inhibit expression of PD-L1 in the tumor. In vivo experiments show that ECN can specifically colonize the core of the tumor and effectively deliver Met to the core of the tumor, enhancing the Met penetration ability in the tumor. On the other hand, Met inhibits the expression of PD-L1 in tumor cells, reverses the immune suppressive microenvironment of the tumor, and recruits CD3+ CD4+ CD8+ T lymphocyte cells to infiltrate the tumor site, ultimately enhancing the antitumor response.

An immunosuppressive microenvironment in AML is driven by PD-L1 expression, kynurenine pathway activation, and low vitamin D levels. These findings suggest potential immunotherapeutic targets and highlight vitamin D's immunomodulatory role.

Endometrial tumors with FOLR1 overexpression had a significantly higher rate of TP53 mutations (P=0.013), while all endometrial tumors with PTEN alterations were negative for FOLR1 (P=0.037). Overall, FOLR1 overexpression was associated with poor prognostic factors, such as advanced clinical stage, increased recurrence rate, higher pathologic T and N stage, poor histologic grade, larger tumor size, lymphovascular invasion, uterine serosa involvement, and shorter progression-free survival.

Pembrolizumab combined with TC (paclitaxel-carboplatin) therapy may be an effective treatment option for selected patients with unresectable in-field recurrent cervical cancer. Further evidence is required to clarify the optimal duration of combination therapy and the timing of transition to immune checkpoint inhibitor maintenance.

In summary, this study developed a risk score model associated with survival outcomes in ccRCC and highlighted a potential role of PLG in tumor progression and immune regulation. These findings provide a basis for further mechanistic studies and clinical validation.

GC subtypes have distinct immune microenvironments that influence prognosis. Our findings highlight the prognostic and therapeutic potential of immune profiling in GC.

P1, N=160, Recruiting, SystImmune Inc. | N=120 --> 160

This study suggests that administering chemotherapy prior to immunotherapy appears to improve OS in patients with advanced EC and GC, particularly when initiated as first-line treatment. These findings highlight the need for further research into biomarkers and personalized treatment strategies to enhance patient outcomes.

A prospective, non-randomized, two-cohort study was designed to evaluate the efficacy of sintilimab combined with chemotherapy in this setting...This preliminary analysis demonstrates that ICI combined with chemotherapy provides durable antitumor activity and a manageable safety profile as neoadjuvant and/or adjuvant therapy for locally advanced PSCC. These results warrant further validation in larger cohorts.

This study deciphered a novel druggable metabolic-epigenetic pathway (lactate-H3K18la-KIF20A-Myc-PD-L1) responsible for immune evasion in HCC. Targeting this axis might offer a promising strategy to reprogram the tumor microenvironment and restore immunotherapy sensitivity.